Ovid Therapeutics (OVID) Q2 2025 earnings summary

Executive summary

• Reported $6.3 million in Q2 2025 revenue, primarily from a one-time licensing payment; no commercial product revenue recognized.

• Net loss of $4.7 million for Q2 2025, compared to net income of $8.5 million in Q2 2024, reflecting lower other income and reduced operating expenses.

• Cash, cash equivalents, and marketable securities totaled $38.3 million as of June 30, 2025.

• Management disclosed substantial doubt about the ability to continue as a going concern, with current resources insufficient for the next 12 months.

• Monetized ganaxolone royalty rights for $7.0 million, strengthening the balance sheet and focusing resources on core pipeline assets.

Financial highlights

• Q2 2025 revenue: $6.3 million, up from $0.2 million in Q2 2024, driven by a one-time licensing payment and royalty agreements.

• Research and development expenses decreased to $6.5 million in Q2 2025 from $12.6 million in Q2 2024, mainly due to program pauses, lower headcount, and restructuring.

• General and administrative expenses fell to $4.9 million in Q2 2025 from $8.1 million in Q2 2024, reflecting cost reductions and restructuring.

• Other income in Q2 2025 was $0.4 million, down from $29.0 million in Q2 2024, which included a $29.0 million gain from royalty monetization liability adjustment.

• Net loss per share for common stock was $(0.06) in Q2 2025, compared to $0.12 earnings per share in Q2 2024.

Outlook and guidance

• Existing cash and marketable securities are not sufficient to fund operations for the next 12 months; additional capital is required.

• Management is considering financing, partnerships, collaborations, or licensing agreements to secure funding.

• If unable to raise capital, may need to reduce expenses, delay, or eliminate R&D programs.

• No guidance provided on future revenue or profitability; continued operating losses expected for the foreseeable future.

• Cash runway projected to support operations and development through early 2H 2026.